Loxo plans to price IPO of 4,384,615 shares between $12.00 and $14.00

Cowen, Stifel, Oppenheimer and JMP Securities to assist with offering

By Devika Patel

Knoxville, Tenn., July 21 – Loxo Oncology, Inc. will sell 4,384,615 common shares in its initial public offering with a 30-day greenshoe option of 657,692 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced June 30.

The shares will be sold at a price expected to fall between $12.00 and $14.00 per share.

Cowen and Co. and Stifel are the joint bookrunning managers. Oppenheimer & Co. and JMP Securities are the co-managers.

Investment funds affiliated with Deerfield Management Co., LP have indicated an interest in investing about $14.5 million, and an affiliate of New Enterprise Associates 14, LP has indicated an interest in investing about $3 million. In addition, some of the company’s principal stockholders and their affiliated entities have indicated an interest in purchasing up to $9 million of the shares.

Proceeds will be used for clinical trials, research and development, working capital and general corporate purposes.

The Stamford, Conn., company develops targeted small-molecule therapeutics for the treatment of cancer in genetically defined patient populations. The company intends to list its common stock on the Nasdaq under the symbol “LOXO.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.